Biomarkers needed to predict progestin response in endometrial cancer-Reference-Cited by-同舟云学术

Biomarkers needed to predict progestin response in endometrial cancer

Published:2017-01-27 Issue:10 Volume:124 Page:1584-1584
ISSN:1470-0328
Container-title:BJOG: An International Journal of Obstetrics & Gynaecology
language:en
Short-container-title:BJOG: Int J Obstet Gy

Author:

Derbyshire AE¹,Ryan NAJ²,Crosbie EJ¹²

Affiliation:

1. Department of Obstetrics and Gynaecology; St Mary's Hospital; Central Manchester University Hospitals NHS Foundation Trust; Manchester Academic Health Science Centre; Manchester UK

2. Division of Molecular and Clinical Cancer Sciences; Faculty of Biology, Medicine and Health; St Mary's Hospital; University of Manchester; Manchester UK

Funder

Central Manchester University Hospitals NHS Foundation Trust Clinical Research Fellowship

Medical Research Council Doctoral Research Fellowship

National Institute for Health Research (NIHR) Clinician Scientist Fellowship

Publisher

Wiley

Subject

Obstetrics and Gynaecology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/1471-0528.14490/fullpdf

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Proteogenomic insights into early-onset endometrioid endometrial carcinoma: predictors for fertility-sparing therapy response;Nature Genetics;2024-04

2. Low‐density lipoprotein receptor‐related protein 5/6 promotes endometrial cancer progression and cancer cell immune escape;Journal of Biochemical and Molecular Toxicology;2024-03-25

3. Serum HE4 predicts progestin treatment response in endometrial cancer and atypical hyperplasia: A prognostic study;BJOG: An International Journal of Obstetrics & Gynaecology;2023-02-15

4. Identification and Validation of an m7G-Related lncRNAs Signature for Prognostic Prediction and Immune Function Analysis in Endometrial Cancer;Genes;2022-07-22

5. Molecular Classification in Patients With Endometrial Cancer After Fertility-Preserving Treatment: Application of ProMisE Classifier and Combination of Prognostic Evidence;Frontiers in Oncology;2022-05-19